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Abstract 
 
We have produced an Fc conjugate of CSF1 with an improved circulating half-life.  
CSF1-Fc retained its macrophage growth-promoting activity, and did not induce 
proinflammatory cytokines in-vitro. Treatment with CSF1-Fc did not produce adverse 
effects in mice or pigs.  The impact of CSF1-Fc was examined using the Csf1r-EGFP 
reporter gene in MacGreen mice. Administration of CSF1-Fc to mice drove extensive 
infiltration of all tissues by Csf1r-EGFP positive macrophages.  The main consequence 
was hepatosplenomegaly, associated with proliferation of hepatocytes. Expression 
profiles of the liver indicated that infiltrating macrophages produced candidate mediators 
of hepatocyte proliferation including urokinase, TNF and IL6.  CSF1-Fc also promoted 
osteoclastogenesis and produced pleiotropic effects on other organ systems, notably the 
testis, where CSF1-dependent macrophages have been implicated in homeostasis. 
However, it did not affect other putative CSF1 targets, notably intestine, where Paneth 
cell numbers and villus architecture were unchanged.  CSF1 has therapeutic potential in 
regenerative medicine in multiple organs.  We suggest that the CSF1-Fc conjugate retains 
this potential, and may permit daily delivery by injection rather than continuous infusion 
required for the core molecule. 
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Introduction 
 
The mononuclear phagocyte system is a family of cells comprising progenitors in the bone 
marrow (BM), circulating monocytes and tissue macrophages
1
. The proliferation, 
differentiation and survival of these cells depends upon macrophage colony-stimulating 
factor (CSF1).  Mutations in the CSF1 locus produce pleiotropic effects on many tissues, 
reflecting the many roles of macrophages in development and homeostasis
2,3
. A subset of 
these effects can be mimicked by prolonged treatment with a blocking antibody against the 
CSF1 receptor (CSF1R)
4
. A Csf1r-EGFP transgene provides a marker for macrophages in 
tissues, and enables monitoring of the impacts of treatments that later tissue macrophage 
numbers
5
.  The effects of the blocking antibody supported the concept that macrophage 
survival/replacement in most tissues, with possible exception of the lung, requires continuous 
CSF1R signalling
4,6
.   
Monocyte and macrophage numbers can be increased above the normal homeostatic levels by 
CSF1 treatment. Recombinant CSF1 has been tested in clinical trials for several indications
2
, 
but has not yet found a clinical application. The original studies when the molecule was 
cloned focussed on cancer therapy as the indication
7
. Further studies have been constrained 
by the cost of the agent.  CSF1 has a very short half-life in the circulation of mice (1.6 hours), 
being cleared by CSF1R-mediated internalisation and degradation by Kupffer cells of the 
liver
8
. Renal excretion becomes the major mechanism of clearance when the receptor-
mediated clearance is saturated. The 150 amino acid active CSF1 protein produced in bacteria 
is well below the renal clearance threshold of around 68kDa (the size of albumin), and 
consequently the majority of any injected bolus dose is rapidly removed by the kidney.  Early 
studies of human CSF1 actions in mice by Hume et al.
2
  used the large glycoprotein form of 
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the protein produced in mammalian cell culture.  It was active with daily injections of 0.5 to 1 
mg/kg. In subsequent studies using the smaller protein expressed in bacteria a 5-10 fold 
higher dose was required to achieve an increase in circulating monocyte numbers
2
.  
When CSF1 was originally identified, it was administered by continuous infusion and was 
well-tolerated
7
 The dose-limiting toxicity was thrombocytopenia, which recovered rapidly 
upon cessation of treatment
7,9
. Recent studies have reinvigorated interest in CSF1 as a 
therapeutic agent in tissue repair
2
. To enable reinvestigation of therapeutic applications of 
CSF1, especially preclinical evaluations in large animals, we sought to increase the half-life 
by producing a conjugate with the Fc region of immunoglobulin
10
. Aside from increasing the 
molecular size, such conjugates bind the recycling neonatal Fc-receptor (FcRN), which 
salvages the protein from endosomal degradation and may allow less frequent dosing of 
patients. The most studied example is Fc-erythropoietin (EPO), which is in clinical use
10
. 
There are several other reports of functional Fc fusion proteins including G-CSF which, like 
EPO, is structurally related to CSF1.  However, the production of active Fc conjugates may 
be complicated by inappropriate formation of disulphide bonds
11
. In the case of CSF1, the 
active protein has three intra-chain disulphides and is a disulphide-linked dimer. The 
additional concern is that a conjugate might potentially link CSF1 to macrophage Fc 
receptors, which could promote, rather than decrease clearance, or might activate the 
macrophages in unanticipated ways
12
.  
The domestic pig has been used extensively in biomedical research, including preclinical 
studies of Fc conjugates of EPO
13. CSF1 from the domestic pig has the advantage of 
providing a molecule that is equally active across all mammalian species examined
14
. We 
produced a pig CSF1 active fragment conjugated to CH-3 region of pig IgG1a. In this paper 
we describe the ability of this molecule to drive a massive expansion of tissue macrophage 
populations in mice. The actions of the molecule in-vivo led to the surprising conclusion that 
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CSF1 is involved in homeostatic control of the size of the liver and has pleiotropic effects in 
several other organ systems. These findings expand the potential applications of CSF1 
therapy in regenerative medicine.  
 
Results 
Production and activity of pig CSF1-Fc.  
A fusion protein comprising pig CSF1 joined to the hinge-CH3 region of pig IgG1a (Fig. 1A) 
was expressed in HEK293F cells and purified using Protein A affinity chromatography under 
contract from Genscript.  We have previously demonstrated that pig CSF1 is biologically 
active on the mouse CSF1R
14
. The activity of CSF1-Fc was tested in parallel with native 
recombinant pig CSF1 on the Ba/F3pCSF1R cell assay previously described
14
 and on pig BM 
cells.  The CSF1-Fc protein was equally active on the cell line, and significantly more active 
on pig BM (Fig. 1B).  Prior to in-vivo studies, we wished to be certain that the CSF1-Fc did 
not have any direct macrophage-activating effect, potentially through cross-linking of Fc 
receptors. Pig BM-derived macrophages (BMDM) were grown in CSF1 as described 
previously
15
 then treated with pig CSF1-Fc or LPS.  Where LPS produced a massive increase 
in TNF secretion there was no detectable response to CSF1-Fc (data not shown). To test the 
effect of the Fc conjugate on clearance, pig serum samples were collected at various time 
points following subcutaneous injection of either CSF1-Fc or CSF1 and assayed using an 
anti-CSF1 antibody ELISA developed in-house (Fig. 1C).  As anticipated, the administration 
of CSF1-Fc achieved a 10-100-fold higher peak concentration than unconjugated CSF1 
alone, and an elevated concentration was maintained for up to 72 hours.   
Previous studies in humans and primates have indicated that CSF1 is relatively well-
tolerated
7,16
.  However, the Fc conjugate could produce a secondary stimulus. An initial study 
indicated that a daily dose of 0.5 mg/kg was sufficient to induce a 2-3 fold increase in total 
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leukocytes after 3 days, and also produced substantial increases in tissue histiocytes in the 
liver (not shown). We subsequently treated a cohort of 13 newborn piglets with 0.5 mg/kg 
every second day for two weeks, and sacrificed them 2 weeks later.  Animals were weighed 
and monitored continuously, and blood taken at days 1, 7, 13 and 24.  As observed in patients 
treated with recombinant CSF1
7,9
, there was an increase in total white blood cells (WBC), 
which was not restricted to monocytes.  Total WBC and total lymphocytes were increased 
transiently even in the control piglets; this was extended by the CSF1-Fc treatment. All of the 
WBC populations declined following the cessation of treatment. There was no evidence of 
increased temperature or behavioural changes during the treatment period, and all animals 
gained weight rapidly (Fig. S1).  In summary, the CSF1-Fc conjugate appears active, safe and 
well-tolerated in a large animal.  
 
CSF1-Fc expands macrophage populations in blood and organs. 
 
As noted in the introduction, the effects of CSF1 mutation in mice suggest that CSF1-
dependent macrophages have many roles in homeostasis. Notwithstanding the apparent 
safety, side effects that have not been considered could constrain therapeutic applications of a 
much more active form of CSF1.  To test the effect of CSF1-Fc in more detail in mice, we 
first performed a dose response study.  We treated daily to maintain continuous elevation of 
CSF1, since there is some evidence of decline in levels after 24 hours. It may be that less 
frequent treatment would produce the same outcome, but this has not been evaluated 
systematically.  A series of 4 daily treatments with CSF1-Fc produced a maximal increase in 
blood leukocytes at 0.5 and 1mg/kg. Administration of 1mg/kg of recombinant pig CSF1 
produced no detectable increase in circulating leukocytes or tissue macrophages, despite the 
equivalent activity in the in vitro assays (data not shown).  We therefore used the dose of 
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1mg/kg for subsequent studies. By contrast to many previous studies, and in the light of the 
known roles of CSF1 in both male and female fertility
3
 , we examined equal numbers of male 
and female mice.  There was a significant increase in total body weight in the CSF1-Fc 
treated group (Fig. 2A). The most obvious effect of the CSF1-Fc was hepatosplenomegaly, 
which was visibly evident upon necropsy, and which accounted for almost all of the body 
weight gain.  Administration of CSF1-Fc doubled the spleen/body weight ratio (Fig. 2B) and 
increased the liver/body weight ratio by 50% (Fig. 2C). There was no difference in gross 
kidney or lung weight or organ/body weight ratios. The total white blood cell count was 
significantly increased in mice treated with CSF1-Fc, mainly due to monocytosis and 
neutrophilia (Fig. 2D-G).  
The Csf1r-EGFP
+
 MacGreen reporter mice
5
 provide a unique tool to monitor the response to 
CSF1-Fc.  The increased numbers of EGFP
+
 cells in the lung, spleen and liver (Fig. 3A) after 
CSF1-Fc treatment was so great that it could be detected as a global increase in total 
fluorescence (Fig. 3B). Increased macrophage numbers were confirmed by F4/80 
immunostaining for both liver and spleen (Fig. 3C). The effect of CSF1-Fc in the lung was 
unexpected. Prolonged treatment of mice with anti-CSF1R antibody was shown to deplete 
alveolar macrophages, but not interstitial macrophages
6
. In the lung of CSF1-Fc treated mice, 
there was a 2-3 fold increase in EGFP
+
 cells that appeared to be confined to the interstitium. 
The increased numbers and diffuse infiltration of EGFP
+
 cells within the spleen of CSF1-Fc 
treated mice was so extensive it was impossible to identify the boundaries of the red and 
white pulp, implying that there was extensive infiltration of the lymphoid follicles by EGFP
+
 
cells (Fig. 3A-B). In the liver, the EGFP reporter gene is expressed solely in Kupffer cells 
which constitute about 8% of the total liver cell population
5
. The relative proportion of 
EGFP
+ 
cells was increased around 2-fold in the CSF1-Fc-treated mice (Fig. 3A-B). The 
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location of the positive cells was unchanged, and was consistent with the sinusoidal location 
of Kupffer cells (Fig. 3C). 
 
Pleiotropic effects of CSF1-Fc treatment. 
 
The close physical and functional interaction between testicular interstitial macrophages 
(TIM) and Leydig Cells (LC) is essential for normal testis function. TIMs have been 
demonstrated to be associated with development and function of LC and CSF1 has also been 
implicated in control of male fertility and testosterone production
17
. To preserve the histology 
of the testis for this application, the mice were perfusion fixed which decreases EGFP 
detection.  Macrophages were localised in the testis of MacGreen mice injected with CSF1-
Fc using anti-GFP antibody and confirmed using the Mac2 antibody, which detects galectin-
3, and the anti-macrophage ER-HR3 antibody (data not shown).  There was a clear increase 
in interstitial macrophage numbers in CSF1-Fc-treated animals compared to controls (Fig. 
4A). To assess the consequence of these changes, we examined the circulating levels of 
testosterone and Luteinizing hormone (LH), which participates in a physiological feedback 
loop with testosterone, in the blood. The CSF-1-deficient op/op mouse was reported to have 
depleted levels of both testosterone and LH, indicating a disruption of the hypothalamic 
feedback loop
17
. We demonstrated a significant increase in circulating testosterone, with no 
difference in circulating LH, in CSF1-Fc-treated animals compared to PBS controls (Fig. 
4B). CSF1 has been inferred to have direct effects on epithelial cell proliferation and 
differentiation in the intestine. The Paneth cells of the crypt appear to be depend upon CSF1 
signaling, and are absent from the CSF1-deficient op/op mouse
18
. The MacGreen reporter 
gene is not detected on any cells within the epithelium in the intestine, including the crypts 
and Paneth cells, but there are large numbers of EGFP
+
 cells in intimate contact with the 
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underlying basement membrane (Fig. S2A).  The lamina propria of MacGreen mice contains 
a very dense network of EGFP
+
 cells
5
.  Against this high background, we did not detect any 
increase in EGFP
+
 cells following CSF1-Fc treatment, nor any overt change in villus 
thickness or architecture. Cryosections were immunostained to detect the Paneth cell marker, 
lysozyme in intestinal crypts.  There was no difference in apparent numbers, location or 
staining intensity between the control and CSF1-Fc treated samples, nor any effect on villus 
architecture or morphology to suggest impacts on epithelial proliferation (Fig. S2B). 
Together with RANK ligand, CSF1 can activate multiple intracellular signalling pathways in 
osteoclasts
2,19
. The administration of CSF1-Fc caused a clear increase in the number of 
TRAP
+ 
osteoclasts within the epiphyseal plate compared to PBS control mice (Fig. 5A-B). 
Within the BM, there was a significant increase in the myeloid:erythroid ratio from the 
normal range of 1.3-1.5 to a ratio of 1.8-2.0 (Fig. 5B).  CSF1 treatment of mice was reported 
to increase the numbers of CSF1 responsive cells within the BM
20
, consistent with more 
recent evidence that it has a direct instructive role on progenitors
21
. Marrow cells were also 
stained with the macrophage specific antibody F4/80 and anti-Ly6C/G (Gr1). CSF1-Fc 
caused a large increase in the proportions of marrow cells that were EGFP
+
, F4/80
+
 and Gr1
+
 
(Fig. 5C). 
  
The origin of the increase in liver and spleen weight in CSF1-Fc treated mice. 
 
In the spleen, the majority of the increase in size was attributable to increased red pulp, and 
also to expansion of the marginal zones (Fig. 6A).  In the liver, the sinusoidal macrophage 
numbers were substantially increased. There was no evidence of haemostasis, no infiltration 
by other leukocytes such as neutrophils that would indicate tissue damage, nor of apoptosis of 
hepatocytes (Fig. 6B). Histological examination revealed numerous mitotic figures in 
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hepatocytes in the treated mice, where they were absent from controls. Accordingly, sections 
of liver, spleen, lung and kidney were stained for proliferating cell nuclear antigen (PCNA).  
There was a significant increase in the number of PCNA
+ 
cells in the liver and spleen of 
CSF1-Fc treated mice (Fig. 7A-B). In the liver, the majority of PCNA
+
 cells were 
hepatocytes (Fig. 7A, black arrow), but the PCNA
+
 cells within the sinusoids resembled 
Kupffer cells (Fig. 7A, red arrow). Both nuclear and cytoplasmic PCNA staining was 
identified in the treated mice livers (Fig. 7A, dashed arrow).  A transition from cytoplasmic 
to nuclear PCNA staining in hepatocytes is also observed in regenerating liver
22
. PCNA
+
 cells 
were distributed throughout the parenchyma. The same pattern of widespread hepatocyte 
proliferation is seen after partial hepatectomy, where new hepatocytes derive from pre-
existing hepatocytes rather than stem cells
23
.  
CSF1-Fc can drive recruitment of cells to the peritoneal cavity, including both Ly6C
+
 
monocytes and granulocytes, and many of the infiltrating cells are actively proliferative
24
. To 
confirm the apparent proliferative capacity of the macrophages in the treated liver, we 
disaggregated the livers of control and CSF1-Fc treated mice following labeling with 
bromodeoxyuridine (BrdU), and examined the phenotype of the macrophages by FACS.  The 
labeling index in the controls was <1%  whereas around 10% of F4/80
+
 Kupffer cells were 
dual positive for the proliferative marker Ki67 and for BrDU labeling in the CSF1-Fc treated 
mice (Fig. 7C). CSF1-Fc also produced a significant increase in splenic PCNA
+
 cells, 
probably reflecting the ability to drive extramedullary haemopoiesis
2
  (Fig. 7A-B). 
  
Microarray data of liver gene expression.  
 
Gene expression arrays were used to determine whether there were any changes in liver 
function and whether there was expression of known hepatocyte growth factors. 2969 
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transcripts were differentially-expressed in the CSF1-Fc treated livers, with 1020 genes 
repressed by CSF1-Fc treatment and 1948 genes induced.  To segregate these data into co-
expressed gene sets that were likely to be expressed by liver cells versus macrophages, and 
genes potentially induced in the macrophages by exposure to LPS in the portal venous blood, 
the liver datasets were analysed alongside data from BMDM cultured in CSF1, with or 
without stimulation with LPS
25
.  Network analysis of the normalised expression data was 
performed using BioLayout Express
3D
 as described previously
25
. This generated a graph of 
2,555 nodes representing distinct transcripts (Fig. 8A). To identify groups of tightly co-
expressed genes, the graph was clustered using the graph-based Markov clustering algorithm 
set at an inflation value (which determines the granularity of the clusters) of 1.8.  This 
generated 45 clusters of co-expressed transcripts with membership sizes ranging from 690 to 
4 nodes.  Fig. 8B shows the average expression profiles of the five largest clusters. Cluster 1 
comprised 690 transcripts collectively repressed in the livers of treated mice and absent or 
low-expressed in the BMDM samples. The gene ontology (GO) annotation indicated 
enrichment for intermediary metabolism, and the list includes numerous enzymes of glucose, 
amino acid and lipid metabolism and cytochrome P450 members.  The most interesting 
members of this cluster were the growth hormone receptor (Ghr), glucagon receptor (Gcgr) 
and insulin receptor (Insr), which could be linked to the changes in metabolism.  Note that 
the repressed cluster did not contain liver-specific genes such as albumin (Alb), which 
indicates inter alia that the influx of macrophages is not sufficient to dilute the hepatocyte 
contribute to the total mRNA pool.  
Cluster 2 (545 transcripts) contained genes expressed in BMDMs (regardless of LPS 
treatment) that were also inducible in CSF1-Fc treated livers.  As anticipated, this cluster is 
clearly enriched in known macrophage-specific genes, including Emr1 (F4/80), Csf1r, Itgam 
(CD11b), CD68, lyz1 (lysozyme) and Mpeg1 consistent with an increase in macrophage 
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representation within the total mRNA pool of treated livers.  The cluster also contains the 
chemokines Ccl2, Ccl3 and Ccl7. Clusters 3 and 6 also contained genes inducible in CSF1-Fc 
treated livers, but in contrast to cluster 2, these 378 transcripts were down-regulated by LPS 
in BMDMs.  Both these clusters contain numerous cell-cycle associated genes, including 
Pcna, identified previously in cluster of a mouse gene expression atlas
26
; they may differ in 
the stages of the cycle they represent.  Cluster 3 also contains the well-characterised CSF1 
target gene, Plau (urokinase plasminogen activator
27
). Their repression in the BMDM is 
consistent with the known ability of LPS to block CSF1 action and cause growth arrest in 
these cells
28
. Finally, and importantly, there is a cluster of genes (Cluster 4) that is induced by 
LPS in the BMDM and also induced, to a lesser extent, in the CSF1-Fc treated livers.  These 
include both pro-inflammatory (Il1, Il6 and Tnf), and anti-inflammatory (Il10) cytokines, 
several chemokines (Cxcl10, Cxcl16) and numerous known targets of interferon signaling 
(e.g. Oas1, Gbp3, Ifit1, Irf7 etc.) identified previously
25,26
.  Hence, the infiltration of the liver 
by macrophages in response to CSF1-Fc is accompanied by induction of classical 
proinflammatory cytokines.  Interestingly, despite the expression of these genes, the inducible 
gene clusters did not include any known hepatocyte acute-phase gene products.   
 
Discussion 
 
This study describes the biological efficacy of an Fc conjugate of CSF1. As shown in Fig. 
1C, the Fc addition to pig CSF1 increased the circulating half-life substantially without 
reducing biological efficacy measured on factor-dependent cells. There was formal 
possibility that the CSF1-Fc would trigger proinflammatory cytokine production by 
signalling through the Fc receptor, CD64
29
.  However, the conjugate did not induce pro-
inflammatory cytokine release in-vitro.  More importantly, in-vivo, there was no evidence of 
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pyrexia or weight loss in treated mice or pigs, nor any infiltration of the tissues by 
granulocytes indicative of acute tissue inflammation.   
 
With the CSF1-Fc, daily injections can maintain a maximally active concentration, and even 
dosing every second day produced elevated monocyte numbers in the pig (Fig S1).  CSF1-Fc 
thus provides a novel reagent to study the role of macrophages in immunity, repair and 
homeostasis
2
. Using this novel new agent, we sought evidence for an effect of excess CSF1 
on CSF1-dependent pathways identified from studies of the op/op mice. There is no evidence 
for the expression of the Csf1r–EGFP transgene within epithelia in any region of the gut5. 
The intimate association of Csf1r-EGFP positive macrophages with the crypt epithelium (Fig. 
S2A) could produce indirect effects, but CSF1-Fc had no effect on epithelial architecture or 
Paneth cell numbers (Fig. S2B). By contrast, and in keeping with known dependence of 
osteoclasts upon CSF1, the administration of CSF1-Fc greatly increased their numbers within 
the epiphyseal plate (Fig. 6A-B). This finding indicates that osteoclast numbers are sensitive 
to the availability of CSF1 in the steady state. There was no change in bone density or 
trabecular architecture in the short time frame examined. The treatment will not necessarily 
reduce bone density, because of the tight coupling of calcium homeostasis.  In fact, Lloyd et 
al.
30
 found that bone density was increased in mice administered high-dose rh-CSF1 for 21 
days and CSF1 can promote intramembranous ossification in a fracture model
31
. These 
findings may reflect a separate role for the abundant population of CSF1-dependent 
macrophages that line bone surfaces
32
. CSF1-Fc could therefore find applications in treatment 
of bone injury and osteoporosis.  
The op/op mouse has deficiencies in both male and female fertility
3
. Previous studies have 
described the close physical and functional relationship between testicular macrophages 
(TIM) and Leydig cells and the role of CSF1 in control of male fertility. CSF1 may also 
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control testosterone production at the level of the hypothalamus and pituitary, by influencing 
the negative-feedback control of LH secretion
17
. We demonstrated that CSF1-Fc increased 
TIM numbers and supported increased testosterone production, over and above the normal 
stimulation provided by pituitary LH (Fig. 4). Furthermore, the observed increase in serum 
testosterone occurred in the absence of a change in circulating LH concentration. These data 
suggest that CSF1 acts both to support testosterone production at the level of the testis, and 
also to disrupt the negative feedback mechanism at the level of the hypothalamus and 
pituitary. Our data indicate for the first time that the availability of CSF1 can control 
testosterone production in an adult animal. As such CSF1-Fc has a potential role as a 
gonadotropin-independent promoter of testicular testosterone production, with potential 
applications in medical and agricultural areas.   
 
The most striking and unexpected effect of CSF1-Fc was the 50% increase in the size of the 
liver (Fig. 2C). By comparison, there was a 15-37% increase in liver weight of mice infused 
with hepatocyte growth factor
33
.  Neither the Csf1r-EGFP transgene
5
, nor Csf1r mRNA
34
 is 
expressed by hepatocytes. So, as in the context of renal regeneration and lung development
35
, 
we favour an indirect effect via macrophage-expressed gene products. Broadly-speaking, 
macrophages elicited by CSF1 treatment fall within the broad M2 or alternative classification 
of activation states
35
, but the actions of CSF1 are quite distinct from those of the alternative 
activator, IL4
24
. Following removal of two-thirds of the liver, the remaining liver becomes 
hyperplastic and mature hepatocytes replicate to restore the original liver mass
36
. As many as 
95% of normally quiescent hepatocytes enter into the cell cycle in response to the priming 
cytokines (TNFα and IL-6) followed by progression through the cell cycle in response to 
growth factors such as hepatocyte growth factor, epidermal growth factor and transforming 
growth factors
36,37
. The treatment with CSF1-Fc largely mimics the effect of partial 
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hepatectomy. The CSF1-dependent expression of urokinase plasminogen activator (Plau) 
may be a key mediator in the response to CSF1-Fc, since this protease is required for the 
release and activation of hepatocyte growth factor
36
. Insulin, glucagon
37
 and growth 
hormone
38
 have also been implicated in liver regeneration, and all three receptors were down-
regulated in the livers of CSF1-Fc treated mice. Both TNFα and IL-6, which were induced in 
the liver of treated mice, have been identified as initiators of liver regeneration after partial 
hepatectomy based upon inhibitory effects of anti-TNFα antibodies39 and defective 
regeneration in mice lacking IL-6
40
.  These cytokines are presumably induced through 
encounter with microbial products arriving in the portal circulation, but the levels are not 
sufficient to produce systemic effects (Fig. 1), nor local infiltration of granulocytes, nor 
induction of classical acute phase genes.  
CSF1 is itself cleared from the circulation by the liver
8
. Liver regeneration does not occur in 
the CSF1 deficient op/op mouse
41
 and is also prevented by macrophage depletion using toxic 
liposomes
42,43
. Together, these observations indicate that CSF1-dependent macrophages are 
necessary for liver regeneration. We reported elsewhere that prolonged anti-CSF1R antibody 
treatment can reduce the size of the liver
4
. The surprising result herein is that CSF1-Fc 
treatment alone is sufficient to promote proliferation in an undamaged liver. The impact of 
CSF1-Fc treatment indicates that there is a simple feedback loop between circulating CSF1 
availability, monocyte production and release by the bone marrow, monocyte extravasation 
and the size of the liver. The remarkable effect of CSF1-Fc on the liver (Fig. 7) has clear 
implications for regenerative therapy. We reported previously that administration of CSF1-
stimulated macrophages via the portal vein can promote repair in chronic liver injury
44
.  Our 
current data suggest that the same outcome may be achieved by the administration of the 
agonist alone without adverse effects.  
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In other regenerative medicine applications, increasing the size of the liver may, or may not, 
be desirable. It could improve the clearance of agents that mediate the pathology. The Fc 
conjugate will certainly improve the efficacy and viability of CSF1 as a treatment in the 
many other organ systems in which it has already been shown to have a beneficial effect
2
 and 
others such as heart
45
 and spinal cord
46
, where macrophages are crucial to repair.  Systemic 
CSF1 administration was recently found to be effective in protection against acute brain 
injury
47
 and promoted the clearance of beta-amyloid deposits in a mouse model of 
Alzheimer’s disease48. The CSF1-Fc provides a new and significantly more cost-effective 
reagent to extend these preclinical studies to large animals.  We have established transgenic 
chicken lines that produce the protein in eggs to produce the large amounts of protein 
required for these studies (unpublished).  An additional advantage of the Fc tag is that the 
protein can also be made using standard commercial protein expression, and readily purified 
by protein A affinity chromatography.  Clearly applications in humans and companion 
animals will require the production of the appropriate species-specific reagents, but the pig 
offers many opportunities for preclinical evaluation.  
Nevertheless, our data also demonstrate that treatment also has pleiotropic effects, most of 
which would be predicted from the complex phenotype of the op/op mouse. The array data 
indicate a global effect on hepatocyte lipid and amino acid metabolism and on responsiveness 
to insulin and glucagon. Taking all of these findings together, CSF1 emerges as a central 
homeostatic regulator. Accordingly, therapeutic applications will need to proceed with 
caution. 
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Materials and methods 
Cloning and expression of pig CSF1-Fc 
 
The sequence corresponding to the active fragment of pig CSF1 (SENCSHMIGDGHLKVLQ 
QLIDSQMETSCQIAFEFVDQEQLTDPVCYLKKAFLQVQDILDETMRFRDNTPNANVI
VQLQELSLRLNSCFTKDYEEQDKACVRTFYETPLQLLEKIKNVFNETKNLLKKDWNI
FSKNCNNSFAKCSSQHERQPEGR) was linked to the hinge-CH3 region of the pig IgG1a 
sequence 
(GTKTKPPCPICPGCEVAGPSVFIFPPKPKDTLMISQTPEVTCVVVDVSKEHAEVQFSW
YVDGVEVHTAETRPKEEQFNSTYRVVSVLPIQHQDWLKGKEFKCKVNNVDLPAPIT
RTISKAIGQSREPQVYTLPPPAEELSRSKVTVTCLVIGFYPPDIHVEWKSNGQPEPEGN
YRTTPPQQDVDGTFFLYSKLAVDKARWDHGETFECAVMHEALHNHYTQKSISKTQ
GK).  This entire region was codon optimised for mammalian expression by GeneArt 
(Invitrogen, CA, USA) and cloned into the expression plasmid pS00524 using HindIII and 
NotI restriction sites engineered into the 5’ and 3’ ends respectively. The resulting plasmid 
was sequenced to ensure ORF integrity and protein was expressed from transfected 
HEK293F or CHO cells.   
 
Isolation of pig CSF1-Fc fusion protein 
 
Pig CSF1-Fc fusion protein produced under contract by Genscript Inc.  Briefly, it was 
isolated using Protein A affinity chromatography.  Briefly, conditioned medium from cell 
culture was centrifuged and loaded onto Protein A Sepharose that was equilibrated with PBS.  
Following loading, the column was washed with PBS and 35 mM Na Acetate pH 5.5.  
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Protein was eluted using a step gradient of 80% B Buffer (35 mM Acetic acid, no pH 
adjustment), 85% B buffer and 100% B buffer.  The 80 and 85% B fractions were pooled 
based on lack of aggregated protein (analytical SEC) and the 100% B fraction was not 
included.  Pooled protein was pH adjusted to 7.2 and dialyzed against PBS.   Purity was 
assessed by mass spectrometry, and endotoxin was certified less than 10EU/mg.  The protein 
migrated as a single band of the expected Mr (85-90kD) on SDS-PAGE, and of 45-50kD 
under reducing conditions.  
 
Cell viability assay 
 
Stable Ba/F3 cells expressing pig CSF1R
14
 were maintained in culture with complete RPMI 
supplemented with 10
4
 Units/ml rh-CSF1 prior to MTT assay. 2x10
4 
cells/well (Ba/F3 cells, 
or 5x10
4 
cells/well (pig BMM) of a 96 well plate were plated in triplicate or quadruplicate 
and treated (serial dilutions of pig CSF1 or CSF1-Fc were added to make a total volume of 
100μl per well.  Cells were incubated for 48 hours at 37°C, 5% CO2.  For Ba/F3pCSF1R 
cells, 10μl of MTT (Sigma Aldrich M5655) stock solution (5mg/ml) was added directly to 
each well to achieve a final concentration of 0.5mg/ml and incubated at 37
°
C for 3 hours 
prior to solubilisation overnight.  For adherent pig BMM cells, the culture medium was 
replaced with 50µl of 1mg/ml MTT solution and incubated for 1 hour at 37
°
C.  The MTT 
solution was removed and tetrazolium salt solubilised with 100μl of solubilisation agent 
(0.1M HCL, 10% Triton x -100 and isopropanol) followed by incubation at 37
°
C with 5% 
CO2 for 10 minutes.  Plates were read at 570nm with reference wavelength of 405nm. 
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Pig CSF1 and CSF1-Fc ELISA 
 
Pig CSF1-Fc-fusion plasma levels were detected using an ELISA, developed in-house using 
human anti-CSF1 antibody (Abcam, ab9693) at 0.3 µg/mL and rabbit anti-pig IgG (Fc) 
biotinylated antibody (Alpha Diagnostic, 90440) at 1:5000 dilution.   Standard protein was 
generated and purified in-house by Zoetis.  Standards were added to each plate along with the 
samples resulting in an 11 point standard range of 2700 ng/mL to 0.046 pg/mL. This allowed 
for quantitation of each sample to a standard curve on every assay plate.  Assay detection was 
done using Pierce High Sensitivity Streptavidin-HRP (1:10,000 dilution) and TMB 
Microwell Peroxidase Substrate System solution (KPL). 
 
Pig CSF1-Fc pharmacokinetic study 
 
Weaner age barrows (castrated male) (<14kg) were assigned to three treatment groups 
receiving a single intravenous (i.v.) or subcutaneous (s.c.) dose as follows:  0.5 mg/kg CSF1 
s.c. (n = 3), 1.2mg/kg CSF1-Fc i.v. (n = 2) or 1.2mg/kg CSF1-Fc s.c. (n = 2).  Blood was 
collected from the jugular into EDTA tubes followed by separation of plasma.  Serial plasma 
samples were obtained from each animal at pre-dose and 5 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8, 
h, 24 h, 48 h, and 72 h post-dose. CSF1 and CSF1-Fc plasma protein concentrations were 
quantitated using ELISA assays.  
 
In vivo mouse study 
 
Csf1r-EGFP
+
 (MacGreen), Csf1r-EGFP
- 
wild-type mice were bred, genotyped and obtained 
from The Roslin Institute Biological Research Facility.  C57BL/6 mice were purchased from 
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Charles River Laboratories (UK).  Approval was obtained from The Roslin Institute’s and 
The University of Edinburgh’s Protocols and Ethics Committees. The experiments were 
carried out under the authority of a UK Home Office Project Licence under the regulations of 
the Animals (scientific procedures) Act 1986.  Male and female 6-10 week MacGreen (n = 8 
per sex), and C57BL/6 mice (n = 12 per sex), were injected subcutaneously with either PBS 
(n=24) or 1mg/Kg pig CSF1-Fc (n=24) for 4 days prior to sacrifice on day 5.  Mice were 
weighed every day prior to injection and before cull.   One mouse from each treatment group 
was tissue perfused with 4% PFA.  Blood was collected by cardiac puncture. 
 
Bone marrow (BM) cells 
 
Bones were stripped carefully of any tissue/muscle placed in 70% ethanol for 1 minute prior 
to PBS for 1 minute. The proximal and distal ends of the femur were cut and cells flushed 
with RPMI.  Cells were re-suspended prior to centrifugation at 400g for 5 minutes and 
counted.  Cells for FACS analysis were harvested as above and prepared at a concentration of 
5x 10
6
 cell/sample.  
 
FACS 
 
BM cells were washed, pelleted and re-suspended in PBS containing 0.1% NaN3, 2% heat 
inactivated FCS, 0.1% BSA) with 2% heat inactivated normal mouse serum (200 µl/sample), 
and incubated on ice for 20 minutes.  Following washes (PBS containing 0.1% NaN3, 0.2% 
heat inactivated FCS, 0.1% BSA: Lo-block), cells were re-suspended in the appropriate 
antibody or isotype control (1:200 of PE anti-mouse F4/80 Biolegend 122616, 1:200 PE anti-
mouse Ly-6G/Ly-6C (Gr-1) Biolegend 108408 or 1:200 PE Rat IgG2b, k isotype control 
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Biolegend 400608) and incubated for 30 minutes. Cells were re-suspended in 400 µl of Lo-
block with 0.1% Sytox Blue (Invitrogen). Samples were analyzed on CyAn (Dako) and 
analysed using Summit 4.1 software (DAKO). 
The liver was perfused via the inferior vena cava and portal vein with PBS and then digested 
in 2mg/ml collagenase D (Sigma Aldrich) at 37
°
C for 30min and passed through a 100μm 
filter. A 7 minute 50G spin was performed to remove hepatocytes. Nonparenchymal cells 
were further purified using a 30% percoll (Sigma) gradient. Cells were stained with fixable 
viability die eFluor 780 then incubated with Fc block (TrustainfcX™, Biolegend) prior to 
staining with CD45 (AF700, Biolegend) and F480 (PECy7, Biolegend). Cells were fixed and 
permeablized using BD Pharminogen BRDU flow kit then stained with antiBRDU (FITC, 
BD Pharminogen) and Ki67 (eF660, eBioscience). Flow cytometry was performed using the 
LSR Fortessa. 
 
Tissue processing 
 
Tissues from perfusion-fixed Csf1r-EGFP
+
 mice were placed into 4% PFA for 2 hours 
followed by overnight incubation in 18% sucrose at 4
°
C.  The following day, tissues were 
embedded in Tissue-Tek OCT compound and frozen in isopentane.  Frozen sections were cut 
(8-12um thick) at -16
°
C using LEICA cryostat and mounted with DAKO fluorescent 
mounting medium (DAKO).  The fluorescence of the EGFP was visualised using Zeiss 
confocal and pictures taken under oil at x400 magnification.  Additional tiled images 
composed of 9 images as above were also generated.  The total fluorescence was analysed 
using Image J.  Tissues from non-perfused mice were weighed and placed in 10% formal 
saline and RNALater.  The left femur after thorough muscle and tissue stripping was placed 
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in formalin at room temperature overnight followed by transfer into 70% ethanol the 
following day.   
Immunohistochemistry 
 
For tissue histology, tissues were processed using Excelsior tissue processor (Thermo Fisher 
Scientific). Sections were then placed in moulds, embedded in paraffin wax 4µm sections cut 
and mounted onto slides (Superfrost Plus, Thermo Fisher Scientific).  Antigen retrieval was 
performed in Proteinase K (Dako S302030) for 10 minutes at 25
°
C. Non-specific protein 
binding was blocked using 2.5% goat serum for 20 minutes at room temperature (Vector 
Laboratories). Endogenous peroxidase activity was blocked using Dako REAL peroxidase 
blocker (Dako REAL blocking agent S202386) for 10 minutes following antibody 
incubations. Sections were incubated at room temperature for 30 minutes using rat anti-F4/80 
(Serotec MCA497G) diluted 1/400 in TBST.  Negative controls were carried out using rat 
IgG at the same concentration as the primary antibody. Visualisation was carried out using 
the secondary reagent Immpress anti rat HRP (Vector Labs MP-7444-15) for 15 minutes at 
room temperature followed by DAB (Newmarket Scientific Monosan Dab substrate kit Cat 
No. MON-APP177) for 10 minutes and DAB enhancer for 3 minutes (Newmarket Scientific 
DAB concentrate Cat No.CO7-25).  For Proliferating Cell Nuclear Antigen (PCNA) sections 
were prepared as above on poly-L-lysine coated slides with antigen retrieved by boiling 10 
mmol/L sodium citrate buffer followed by blocking for endogenous peroxidase activity with 
3% H2O2 in methanol for 10 minutes. Immunohistochemistry was performed using PCNA 
staining kit (Invitrogen, 93-1143) as per manufacturer’s instructions.  
Mouse femurs were decalcified using 14% EDTA (pH7) for 3 days at room temperature, 
dehydrated and embedded in wax for cutting of sections.  TRAP
+
 cells were identified using 
an Acid Phosphatase kit (Sigma-Aldrich 387) according to manufacturer’s instructions.  
Ac
ce
pte
d m
nu
sc
rip
t
ACCEPTED ARTICLE PREVIEW 
© 2014 The American Society of Gene & Cell Therapy. All rights reserved 
For detection of lysozyme in intestinal crypts, 4% paraformaldehyde-fixed sections were 
permeabilized with 50% methanol for 20 minutes before immunostaining with anti-lysozyme 
monoclonal antibody. Appropriate species and immunoglobulin isotype control antibody 
were used as controls. Species-specific Alexa-Fluor 594 (red; Invitrogen, Paisley) secondary 
antibody dye was used and sections were counterstained with Alexa-647 Phalloidin (blue; 
Dako, Ely). Sections were mounted in fluorescent mounting medium (Dako, Ely) and 
examined using a Zeiss LSM5 confocal microscope (Zeiss, Welwyn Garden City). 
For detection of macrophages in the testis, samples were fixed in 4% paraformaldehyde at 
4
°
C for 24 hours, and then moved to PBS, prior to analysis. Sections were deparaffinized, 
rehydrated and antigen retrieved using a citrate buffer epitope retrieval method (10 Psi (0.68 
atm), 125
°
C, 30 min, in citrate buffer pH 6.0) before blocking of endogenous peroxidase and 
nonspecific binding sites. Anti-Mac 2 (Cedarlane labs, Cat. No. CL8942) was applied at 
1:500 in normal horse serum, and incubated at 4
°
C for 24 hours, followed by incubation for 
secondary detection (Vector, immpressTM, Reagent Kit, Cat. No. MP-7401), for one hour.  
Samples were washed in TBS, and DAB detection (Vector, ImmPACT™ Peroxidase 
Substrates, Cat. No. SK-4105) was used to resolve sites of immunolocalization, while 
hematoxylin was used as counterstain. Sections were then mounted for downstream analysis. 
And visualised using an Olympus Research Microscope AX70 Provis, Scotia, NY, USA, 
software:  AxioVision Rel.4.8).  
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Hormone assays 
 
Quantification of circulating hormones was carried out as previously described
49,50
. 
 
Statistical analysis 
 
Data on body weight changes, complete blood counts, organ weights, CSF1, CSF1-Fc and 
IGF-1 ELISA were analysed using a Mann-Whitney test or Kruskal-Wallis test with Dunn’s 
multiple comparison test.  Results are presented as either individual value with the mean + 
standard error of the mean (SEM) or group mean + SEM.  All analyses were performed using 
GraphPad Prism 5.0 (GraphPad Software Inc, San Diego, CA).  A P value < 0.05 was 
considered statistically significant.  
 
Microarray 
 
RNA was extracted from mouse liver using RNA Bee as per manufacturer’s instructions.  
RNA integrity and quality was assessed using Following the RNA 6000 LabChip Kit 
(Agilent).  Samples with a RNA integrity number (RIN) greater than 7 was used for 
microarray.  Microarray was performed by ARK Genomics, The Roslin Institute.  50ng Total 
RNA was amplified using the Nugen Pico SL kit, 2.5ug of the resulting cDNA was biotin 
labelled using the Nugen Encore labelling kit using the half volume protocol.  The biotin 
labelled product was prepared for hybridisation according to the Nugen protocol for 
Affymetrix Gene Titan hybridisation, using the Affymetrix Gene Titan Hybridization Wash 
& Stain Kit for WT Array Plates (PN 901622).  The samples were hybridised to Affymetrix 
Mouse Gene 1.1 ST Array plates using the appropriate Hyb-Wash-Scan protocol for this plate 
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and the Gene Titan Hyb Wash Stain kit for the reagents (Affymetrix).  Image generation and 
the resulting CEL files for analysis were produced in Affymetrix® GeneChip® Command 
Console® Software (AGCC) version 3.0.1. Initial QCs were performed in Expression 
Console. The obtained AffymetrixCEL files were imported into the Genomics Suite software 
package version 6.13.0213 (Partek software. Copyright, ©2012. Partek Inc.) 
Expression data from the liver +/- CSF1-Fc study was analysed alongside that of BMDM 
data generated from the same strain of mice (C57BL/6) (see BMDM method below).  A 
network analysis of the normalised expression data was performed using BioLayout 
Express
3D
. (www.biolayout.org) Using this tool, a Pearson correlation matrix of a transcript-
to-transcript profile comparison was used to filter for expression correlation relationships of r 
> 0.96 across the microarray samples. Nodes within the network graph represent transcripts 
and the edges between them represent expression correlations above the set threshold (r 
>0.96 in this case). To identify groups of tightly co-expressed genes, the graph was clustered 
using the graph-based clustering algorithm MCL set at an inflation value (which determines 
the granularity of the clusters) of 1.8.  Gene lists associated with the clusters were exported 
for GO annotation analysis (Biological and Metabolic Processes Level-FAT) using the 
DAVID (Database for Annotation, Visualization and Integrated Discovery) tool. GEO 
accession No. GSE52636. 
 
BMDM production for microarray 
 
BMDM were prepared as above from C57BL/6J mice and cultured for 6 days in RPMI 1640 
(Sigma-Aldrich, Gillingham, UK) supplemented with 10% heat inactivated fetal bovine 
serum (HIFBS) (Sigma-Aldrich), 25 U/ml penicillin (Invitrogen, Paisley, UK), 25 μg/ml 
streptomycin (Invitrogen), and 2 mM L-glutamine (Invitrogen) and 10,000 U/ml CSF1 on 10 
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cm
2
 bacteriological plastic plates.  On day 6 cells were harvested, counted, re-suspended in 
complete medium with 10,000 U/ml CSF1 and seeded into 24-well tissue culture plates at a 
density of 200,000 cells/well.  24 h later, (day seven) C57BL/6 derived macrophages were 
treated with 50ng/ml LPS at harvested 8h post-treatment, or harvested as untreated (control) 
macrophages. GEO accession No. GSE44292 
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Legends to Figures 
Fig. 1:  Pig CSF1-Fc produces viable CSF1 dependent proliferation in-vitro and has 
extended plasma half-life in-vivo 
 
(A) CSF1-Fc molecule was produced by CSF1 joined to the hinge-CH3 region of pig IgG1a. 
(B) CSF1 dependent Ba/F3pCSF1R cells were cultured in rh-CSF1, harvested, washed twice 
in PBS and plated for the optimised cell viability assay with either pig CSF1 or pig CSF1-Fc 
for 48 hours.  Pig BM cells were flushed from an adult pig rib and placed in culture with 
either pig CSF1 or pig CSF1-Fc for 48 hours.  Following addition of MTT solution and 
solubilisation, optical density was read at 570nm using a plate reader.  Results are the average 
of triplicate determinations + SEM from three experiments. (C) Three weaner pigs were 
injected with either 0.5 mg/Kg or 1.2 mg/Kg pig CSF1 or Fc CSF1-Fc respectively and blood 
collected at time points above for CSF1 and Fc CSF1-Fc levels to be determined by ELISA. 
The mean + SEM is graphed. 
 
Fig. 2:  Effect of CSF1-Fc on body weight, organ weights, and white blood cell counts 
Mice were injected with PBS or 1 µg/g pig CSF1-Fc for four days prior to sacrifice on day 5.  
Blood was collected into EDTA tubes post-mortem and complete blood count assessment 
performed. Graphs show the mean + SEM.  Significance is indicated by *p<0.05, **p<0.01, 
***p<0.001 using a Mann-Whitney test.  n = 20 mice per group for weights and n = 12 mice 
per group for blood cell counts (A) Body weight was recorded before each injection.  Total 
body weight change over the duration of the experiment was graphed (B) Liver/body weight 
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ratio (C) Spleen/body weight ratio (D) Total white blood cell count (E) Monocyte number (F) 
Neutrophil number (G) Lymphocyte number. 
 
Fig. 3:  Effect of CSF1-Fc on tissue macrophage populations 
Mice were injected with PBS or 1 µg/g pig CSF1-Fc for four days prior to sacrifice on day 5.  
(A) Organs from Csf1r-EGFP
+ 
mice were removed post-mortem and frozen in OCT prior to 
cutting and examination of EGFP
+
 cells.  Tiled images of 3x3 x400 field of view were 
generated. Bar = 50µm RP=red pulp, WP=white pulp (B) The total number of EGFP
+ 
cells 
were calculated along with mean total fluorescence + SEM from five representative 
images/mouse/organ. A Kruskal-Wallis test with Dunn’s multiple comparison test was 
performed with significance set as *p<0.05, **p<0.01, ***p<0.001. (C) Formalin fixed liver 
and spleen tissue was prepared and stained for F4/80.  n = 12 mice per group. 
 
Fig. 4:  Effect of pig CSF1-Fc on male reproductive tract 
Mice were injected with PBS or 1 µg/g pig CSF1-Fc for four days prior to sacrifice on day 5. 
Serum was collected as well as tissue, which was fixed and processed as described in 
materials and methods. Graphs show the mean + SEM.  Significance is indicated by *p<0.05 
using unpaired t-tests. (A) Representative sections show macrophages within the testicular 
interstitium, stained with a macrophage marker, Mac2. Bar = 50µM. (B) Serum levels of 
testosterone and (C) Luteinizing hormone. 
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Fig. 5: Effect of pig CSF1-Fc on BM cells and bone.   
Mice were injected with PBS or 1 µg/g pig CSF1-Fc for four days prior to sacrifice on day 5.  
The right femur from each mouse was harvested and prepared for histological examination.  
All graphs show the mean + SEM.  Significance is indicated by *p<0.05, **p<0.01, 
***p<0.001 using a Mann-Whitney test (A) BM cells were flushed from the femurs post-
mortem and prepared for FACS as described in materials and methods. The percentage of 
F4/80 and Gr1 cell populations were determined by exclusion of dead cells using Sytox blue.  
n = 12 mice/group. (B) TRAP IHC was performed. Black arrows represent OCL in 
epiphyseal plate. The number of positive cells in each section was counted. n = 4 mice/group. 
(C) The myeloid:erythroid ratio was determined and graphed.  n = 4 mice/group. 
 
Fig. 6:  Effect of pig CSF1-Fc on liver and spleen pathology  
Mice were injected with PBS or 1 µg/g pig CSF1-Fc for four days prior to sacrifice on day 5.  
The spleen (A) and liver (B) were removed post-mortem and placed in 10% formal saline 
prior to sections being cut and stained with H&E for blind histological examination.  
Representative images are shown. F=follicle, MZ=marginal zone, RP=red pulp. Arrows 
represent sinusoidal infiltrate. 
 
Fig. 7:  Effect of pig CSF1-Fc on liver PCNA and Ki67 as markers of proliferation 
Mice were injected with PBS or 1 µg/g pig Fc CSF1-Fc for four days prior to sacrifice on day 
5.  (A) Following harvest of organs and preservation in 10% formal saline, 8 µm sections 
were cut and PCNA immunohistochemistry performed.  Slides from each mouse were 
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examined for the presence of PCNA
+
 cells (brown colour) and a representative image is 
shown. Black arrow= bi-nucleate hepatocyte, dashed arrow= cytoplasmic PCNA staining, red 
arrow= Kupffer cells. MF = mitotic figure. PV = portal vein. Bar = 100µm. (B) The mean 
number of PCNA
+
 cells + SEM is graphed. Significance is indicated by *p<0.05, **p<0.01, 
***p<0.001 using a Mann-Whitney test. (C) Following PBS perfusion, the liver was 
removed, digested and non-parenchymal cells were purified. Live CD45
+
F4/80
+
 cells were 
stained for BRDU and Ki67.  
 
Fig. 8:  Network analysis of liver transcripts post pig CSF1-Fc treatment 
Expression data for mouse livers +/- CSF1-Fc (n=3) was analysed alongside that of 
BMDM expression data (+/- LPS). (A) A network graph of transcript-to-transcript 
Pearson correlation relationships was filtered to show relationships of r >0.96, resulting 
in a graph of 2,555 nodes (transcripts) connected by 265,108 edges (Pearson correlation 
relationships). The graph was then clustered using the MCL clustering algorithm into 
groups of co-expressed genes. Nodes with the same colour belong to the same cluster of 
co-expressed genes and tend to be highly connected within the network. (B) Expression 
data for five clusters with each point on the graph representing an individual mouse: 
Cluster 1 (690 transcripts), GO terms: oxidation-reduction; carboxylic acid catabolic 
process; organic acid catabolic process; fatty acid metabolic process; cellular amino acid 
catabolic process, E.g. Genes: Abcb11, Abcb4, Abcb6, Acaa1b, Acacb, Acad8, Acsf2, 
Adh4, Aldh4a1, Car1, Ces1d, Ces1e, Ces1f, Ces2a, Cyp1a2, Cyp2d10, Cyp2d9, Cyp2je, 
Dio1, Fitm2, Glo1, Igfals, Insr, Lipc, Nr1h4, Nr1i2, Scp2, Slc15a5, S1c17a2, S1c19a2, 
Slc37a4, Slc6a9, Ugt2b5, Ugt3a1, Cluster 2 (545 transcripts), GO terms: actin filament-
based process; (actin) cytoskeleton organisation; chemotaxis; mononuclear cell 
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proliferation; leukocyte proliferation; leukocyte activation, E.g. Genes: Actg1, Actn1, 
Anxa1, Arpc1b, Arpc2, Atp1a3, Ccl2, Ccl3, Ccl7, Ccnb1, Cd33, Cd68, Csf1r, Csf2ra, 
Csf2rb, Ctsd, Ctss, Itgam, Lilra6, Mpeg1, Prkcb, S100a4, Scl11a, Slc25a4, Snx1, Cluster 
3 (378 transcripts), GO terms: cell cycle; cell cycle phase/process; mitotic cell cycle; cell 
division; M phase; nuclear division; mitosis, E.g. Genes: Aurka, Brca1, Bub1, Bub1b, 
Ccna2, Ccnd1, Ccne1, Cdc6, Cdca2, Cdca5, Cdk4, Cenpf, Cenpn, Cenpo, Chaf1a, 
Chek1, Chek2, E2f1, E2f2, Etv1, Incenp, Kif11, Kif14, Kif22, Kif23, Kif24, Mcm2, Mcm3, 
Mcm5, Pola2, Pold1, Polh, Rohb, Tnfrsf21, Tubb5, Wee1, Cluster 4 (287 transcripts), GO 
terms: immune response; regulation of cytokine production; defense response; response 
to virus; inflammatory response; positive regulation of cytokine production, E.g. Genes: 
Atf3, Casp1, Casp4, Cd14, Cd40, Cflar, Csf3r, Gbp2, Gbp3, Gbp5, H2-Ab1, H2-M3, 
Ifi203, Ifi44, Ifit1, Il10, Il15, Il6, Irf5, Irf7, Mx1, Myd88, Nod1, Oas1a, Oas2, Oas3, 
Psmb8, Slamf8, Slfn2, Slfn5, Stat1, Tap1, Tlr1, Tlr2, Tlr6, Tlr7, Tnf, Vasp, Cluster 5 (138 
transcripts), GO terms: immune response; chemotaxis; G-protein signalling; cell 
adhesion; cAMP-mediated signalling; regulation of blood pressure, E.g. Genes: Ace, 
C1qa, Cd163, Cd38, Cd7, Clec4n, Cxcl14, Ear1, Emr4, Gsta1, Ifitm6, Ly6a, Pld1, 
Siglec1, Slc16a5, Tagln, Trem3, Tspan15. 
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Fig. S1: Effect of pig CSF1-Fc on piglet growth and white blood cell counts 
(A) Newborn piglets from a single litter were assorted into two groups so that each was 
size-matched with a sibling and the average weight of the group was identical.  Piglets 
were injected (red *) on days 1, 3, 5, 7, 9 and 11 with 0.5 mg/Kg pig CSF1-Fc. Body 
weight was recorded before each injection and every 2-3 days until the end of the 
experiment. The mean body weight for the treatment and control groups was recorded. 
(B) Blood samples were obtained from piglets 24 hours after birth before any injections 
(day 1) and subsequently on days 7 (24 hours after the 3
rd
 injection), day 13 (24 hours 
after the 6
th
 injection) and day 24 (cull day). Blood was collected and full blood count 
including manual differential count performed. The error bars represent SEM. 
 
Fig. S2:  Effect of pig CSF1-Fc on intestine 
 
(A) Intestines from Csf1r-EGFP
+
 mice were removed post-mortem and frozen in OCT 
prior to cutting and examination of EGFP
+
 cells. Dotted line represents crypt of 
Lieberkühn. (B) Mice were injected with PBS or 1 µg/g pig CSF1-Fc for four days prior 
to sacrifice on day 5. PFA-fixed 5µm Cryosections of intestine were immunostained to 
detect lysozyme (red) in intestinal crypts; sections were counter-stained for f-actin (blue). 
Representative images are shown from n = 4 mice/group. 
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Figure 6 
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Figure 7 
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